Patents Assigned to AstraZeneca
  • Compounds
    Patent number: 11453644
    Abstract: The present specification provides a compound of formula (I): or a pharmaceutically acceptable salt thereof; a process for preparing such a compound; and to the use of such a compound in the treatment of an ROR? and/or ROR?t mediated disease state.
    Type: Grant
    Filed: March 26, 2021
    Date of Patent: September 27, 2022
    Assignee: AstraZeneca, AB
    Inventors: Frank Narjes, Roine Ingemar Olsson, Stefan Von Berg, Sarah Lever
  • Halo-substituted piperidines as orexin receptor modulators
    Patent number: 11434236
    Abstract: The present application relates to certain halo-substituted piperidine compounds, pharmaceutical compositions containing them, and methods of using them, including methods for treating substance addiction, panic disorder, anxiety, post-traumatic stress disorder, pain, depression, seasonal affective disorder, an eating disorder, or hypertension.
    Type: Grant
    Filed: December 9, 2020
    Date of Patent: September 6, 2022
    Assignees: ASTRAZENECA AB, EOLAS THERAPEUTICS, INC.
    Inventors: Theodore M. Kamenecka, Jörg Holenz, Steven Wesolowski, Yuanjun He, Roland Bürli
  • Systems and methods for dispensing a statin medication over the counter
    Patent number: 11430555
    Abstract: A method is provided for treatment of atherosclerotic cardiovascular disease in a subject in need thereof by administering a statin pharmaceutical composition to the subject when the subject is qualified for over-the-counter access to the statin pharmaceutical composition. In some embodiments, the statin pharmaceutical composition includes atorvastatin, fluvastatin, lovastatin, pitavastatin, pravastatin, rosuvastatin, or simvastatin as an active ingredient.
    Type: Grant
    Filed: December 23, 2020
    Date of Patent: August 30, 2022
    Assignee: ASTRAZENECA UK LIMITED
    Inventors: James Blasetto, Judy Firor, David Guiga, William Mongan, Robert Prybolsky, Richard L. Skelly
  • Arginase inhibitors and methods of use thereof
    Patent number: 11420984
    Abstract: Disclosed are compounds of formula (Ia) or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising compounds of formula (Ia) and methods of using the same for treating cancer or a respiratory inflammatory disease and inhibiting arginase: wherein R1 is —NHR1a; R1a is —H or —C(O)CH(R1b)NHR1c; R1b is selected from —H, —(C1-C4) alkyl and CH2OR1d; R1c is —H; or R1b and R1c, together with the atom to which they are attached, form a 5-membered heterocyclic ring; and R1d is H or —CH3.
    Type: Grant
    Filed: February 15, 2019
    Date of Patent: August 23, 2022
    Assignee: AstraZeneca AB
    Inventors: Scott Nathan Mlynarski, Tyler Grebe, Sameer Kawatkar, Maurice Raymond Verschoyle Finlay, Iain Simpson, Jianyan Wang, Steve Cook, Dedong Wu
  • Methods for lowering blood pressure with a dihydropyridine-type calcium channel blocker pharmaceutical composition
    Patent number: 11417416
    Abstract: A method is provided for lowering blood pressure in a subject in need thereof by administering a dihydropyridine-type calcium channel blocker pharmaceutical composition to a subject qualified for over-the-counter access to the dihydropyridine-type calcium channel blocker pharmaceutical composition. In some embodiments, the dihydropyridine-type calcium channel blocker pharmaceutical composition includes isradipine, nifedipine, or nisoldipine. In some embodiments, the dihydropyridine-type calcium channel blocker pharmaceutical composition includes 3-O-ethyl 5-O-methyl 2-(2-aminoethoxymethyl)-4-(2-chlorophenyl)-6-methyl-1,4-dihydropyridine-3,5-dicarboxylate or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: June 13, 2019
    Date of Patent: August 16, 2022
    Assignee: ASTRAZENECA UK LIMITED
    Inventors: Richard L. Skelly, Judy Firor
  • Tetracyclic heteroaryl compounds
    Patent number: 11407765
    Abstract: The specification relates to compounds of Formula (I) and pharmaceutically acceptable salts thereof. The specification also relates to processes and intermediates used for their preparation, pharmaceutical compositions containing them and their use in the treatment of cell proliferative disorders.
    Type: Grant
    Filed: May 7, 2019
    Date of Patent: August 9, 2022
    Assignee: AstraZeneca, AB
    Inventors: Jason Grant Kettle, Sharanjeet Kaur Bagal, Andrew John Eatherton, Shaun Michael Fillery, Graeme Richard Robb, Scott Gibson Lamont, Paul David Kemmitt, Frederick Woolf Goldberg
  • [1,2,4]triazolo[4,3-b]pyridazines for use in the treatment of proliferative diseases
    Patent number: 11407755
    Abstract: The invention concerns compounds of Formula (I) or pharmaceutically-acceptable salts thereof, wherein R1, R2 and n have any of the meanings defined hereinbefore in the description; processes for their preparation, pharmaceutical compositions containing them and their use as anti-proliferative and/or cell-killing agents.
    Type: Grant
    Filed: July 16, 2020
    Date of Patent: August 9, 2022
    Assignee: AstraZeneca AB
    Inventors: Robert Hugh Bradbury, Alfred Arthur Rabow, Michael James Waring, James Francis McCabe, Steven Christopher Glossop, Arshed Mahmood, Zoe Ann Cotter
  • METHODS OF USING LIPID NANOPARTICLES FOR DELIVERING MODIFIED RNA ENCODING A VEGF-A POLYPEPTIDE AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME
    Publication number: 20220226243
    Abstract: The disclosure relates to nanoparticles comprising a lipid component and a modified RNA encoding a VEGF-A polypeptide. Aspects of the disclosure further relate to uses of nanoparticles comprising a lipid component and a modified RNA encoding a VEGF-A polypeptide, for improving wound healing in a subject. Some aspects of the disclosure relate to the topical administration of nanoparticles comprising a lipid component and a modified RNA.
    Type: Application
    Filed: May 8, 2020
    Publication date: July 21, 2022
    Applicant: AstraZeneca AB
    Inventors: Kenny Mikael Hansson, Maria Wågberg, Nils Bergenhem
  • COMPOSITIONS FOR SKIN AND WOUNDS AND METHODS OF USE THEREOF
    Publication number: 20220226438
    Abstract: This disclosure relates to mRNA therapy for (i) the promotion and/or improvement of wound healing, (ii) the prevention and/or reduction of scar formation at a wound, (iii) the reduction of the visibility of a scar, and/or (iv) the treatment of epidermolysis bullosa. mRNAs for use in the invention, when intradermally (e.g., using microneedles) or topically administered in vivo, encode a wound healing polypeptide (e.g., a growth factor, a cytokine, a chemokine, a protease inhibitor, or a collagen).
    Type: Application
    Filed: May 8, 2020
    Publication date: July 21, 2022
    Applicant: AstraZeneca AB
    Inventors: Kenny Mikael Hansson, Maria Wågberg, Nils Bergenhem
  • Medicament dispensing system and dispensing method
    Patent number: 11382836
    Abstract: A dispensing system (2) and method for dispensing unit dosage forms (38) from a blister pack (30) is disclosed. The system (2) comprises a housing (4) for receiving a blister pack (30), the blister pack (30) having a plurality of cavities (32) with at least one unit dosage form (38) sealed in each of the cavities (32), the housing (4) comprising at least one housing aperture. The system (2) also comprises a sensing layer comprising a plurality of apertures, each sensing layer aperture configured to substantially align with a corresponding one or more of the plurality of cavities (32) of the blister pack (30) when a blister pack (30) is received in the housing (4) and at least one sensing region. The system (2) further comprises an electronics unit and a power source for providing voltage to the sensing layer.
    Type: Grant
    Filed: July 5, 2018
    Date of Patent: July 12, 2022
    Assignee: ASTRAZENECA AB
    Inventors: Fredrik Jonsson, Lubomir Gradinarsky
  • Methods for preventing or treating certain disorders by inhibiting binding of IL-4 and/or IL-13 to their respective receptors
    Patent number: 11382951
    Abstract: The present disclosure relates to methods of treating, ameliorating or preventing a disorder comprising administering a therapeutically effective amount of a composition comprising a protein which inhibits the ligand of Uniprot #P05112 and/or the ligand of Uniprot #P35225 from binding to their respective receptors to a subject in need thereof. In some embodiments, the disorder is preferably associated with an increase of the Th2 immune response. In some embodiments, administration is preferably locally to the lung in order to treat, ameliorate or prevent allergic asthma, rhinitis, conjunctivitis, lung fibrosis, cystic fibrosis, chronic obstructive pulmonary disease, pulmonary alveolar proteinosis or adult respiratory distress syndrome.
    Type: Grant
    Filed: November 5, 2020
    Date of Patent: July 12, 2022
    Assignees: Pieris Pharmaceuticals GmbH, AstraZeneca AB
    Inventors: Andreas Hohlbaum, Laurent Audoly, Beverly Koller
  • Pyridine and pyrimidine derivatives
    Patent number: 11352369
    Abstract: Provided are a series of novel pyridine or pyrimidine derivatives which inhibit CDK9 and may be useful for the treatment of hyperproliferative diseases. In particular the compounds are of use in the treatment of proliferative disease such as cancer including hematological malignancies such as acute myeloid leukemia, multiple myeloma, chronic lymphocytic leukemia, diffuse large B cell lymphoma, Burkitt's lymphoma, follicular lymphoma and solid tumors such as breast cancer, lung cancer, neuroblastoma and colon cancer.
    Type: Grant
    Filed: July 17, 2020
    Date of Patent: June 7, 2022
    Assignee: ASTRAZENECA AB
    Inventors: Bernard Barlaam, Christopher De Savi, Janet Hawkins, Alexander Hird, Michelle Lamb, Kurt Pike, Melissa Vasbinder
  • Methods for treating erectile dysfunction with a cGMP-specific phosphodiesterase 5 inhibitor pharmaceutical composition
    Patent number: 11348670
    Abstract: A method is provided for treating erectile dysfunction in a subject in need thereof by administering a cGMP-specific phosphodiesterase 5 (PDE5) inhibitor pharmaceutical composition to a subject qualified for over-the-counter access to the PDE5 inhibitor pharmaceutical composition. In some embodiments, the PDE5 inhibitor pharmaceutical composition includes tadalafil or vardenafil.
    Type: Grant
    Filed: June 13, 2019
    Date of Patent: May 31, 2022
    Assignee: ASTRAZENECA UK LIMITED
    Inventors: Richard L. Skelly, Judy Firor
  • Deep learning method for predicting patient response to a therapy
    Patent number: 11348231
    Abstract: A method for indicating how a cancer patient will respond to a predetermined therapy relies on spatial statistical analysis of classes of cell centers in a digital image of tissue of the cancer patient. The cell centers are detected in the image of stained tissue of the cancer patient. For each cell center, an image patch that includes the cell center is extracted from the image. A feature vector is generated based on each image patch using a convolutional neural network. A class is assigned to each cell center based on the feature vector associated with each cell center. A score is computed for the image of tissue by performing spatial statistical analysis based on classes of the cell centers. The score indicates how the cancer patient will respond to the predetermined therapy. The predetermined therapy is recommended to the patient if the score is larger than a predetermined threshold.
    Type: Grant
    Filed: December 6, 2019
    Date of Patent: May 31, 2022
    Assignee: AstraZeneca Computational Pathology GmbH
    Inventors: Guenter Schmidt, Nicolas Brieu, Ansh Kapil, Jan Martin Lesniak
  • Chemical compounds
    Patent number: 11325906
    Abstract: The present invention relates to azaquinolone compounds of Formula (I), and their use in medicine.
    Type: Grant
    Filed: July 17, 2020
    Date of Patent: May 10, 2022
    Assignee: ASTRAZENECA AB
    Inventors: Jeffrey Wallace Johannes, Sudhir Mahadeo Hande, Sebastien Louis Degorce, Martin John Packer
  • Composition for inhalation
    Patent number: 11311558
    Abstract: The invention relates to a formulation comprising formoterol and budesonide for use in the treatment of respiratory diseases. The composition further contains HFA 227, PVP and PEG, preferably PVP K25 and PEG 1000.
    Type: Grant
    Filed: March 27, 2020
    Date of Patent: April 26, 2022
    Assignee: AstraZeneca AB
    Inventors: Nayna Govind, Maria Marlow
  • Gene modification assays
    Patent number: 11254928
    Abstract: Provided herein, in some embodiments, are nucleic acid-based tools that may be used for high-throughput functional genomics studies as well as for the generation of knockout (gene inactivation or deletion) or knockin (gene activation or insertion) cell lines. Tools of the present disclosure include an “activatable reporter cassette,” a guide RNA construct and a nuclease that can be used together, for example, to modify and isolate targeted cells of interest.
    Type: Grant
    Filed: January 13, 2017
    Date of Patent: February 22, 2022
    Assignee: ASTRAZENECA AB
    Inventors: Marcello Maresca, Amir Taheri-Ghahfarokhi, Mohammad Bohlooly-Yeganeh, Lorenz M. Mayr
  • PCSK9 inhibitors and methods of use thereof
    Patent number: 11248001
    Abstract: The invention relates to novel heteroaryl compounds of Formula (I) and pharmaceutical preparations thereof. The invention further relates to methods of treating or preventing cardiovascular diseases, and methods treating sepsis or septic shock, using the novel heterocyclic compounds disclosed herein.
    Type: Grant
    Filed: January 16, 2020
    Date of Patent: February 15, 2022
    Assignee: AstraZeneca AB
    Inventors: Michael H. Serrano-Wu, Mark Chambers, Erica Goldsmith, Jason Tierney, Karamjit Jandu, David Clark, Paul Hinchliffe
  • Protein kinase B inhibitors
    Patent number: 11236095
    Abstract: The invention relates to a novel group of compounds of Formula (I) or salts thereof: wherein Y, Z1, Z2, R1, R4, R5 and n are as described in the specification, which may be useful in the treatment or prevention of a disease or medical condition mediated through protein kinase B (PKB) such as cancer. The invention also relates to pharmaceutical compositions comprising said compounds, methods of treatment of diseases mediated by PKB using said compounds and methods for preparing compounds of Formula (I).
    Type: Grant
    Filed: April 7, 2020
    Date of Patent: February 1, 2022
    Assignee: ASTRAZENECA AB
    Inventors: Paul David Johnson, Andrew Leach, Richard William Arthur Luke, Zbigniew Stanley Matusiak, Jeffrey James Morris
  • Process for the preparation of osimertinib (AZD9291) or a salt thereof, and “AZD9291 Aniline” or a salt thereof
    Patent number: 11180477
    Abstract: An improved chemical process for the manufacture of the compound of Formula (I), which is useful, for example, as a late-stage chemical intermediate in the production of osimertinib (AZD9291) and pharmaceutically acceptable salts thereof.
    Type: Grant
    Filed: January 31, 2017
    Date of Patent: November 23, 2021
    Assignee: AstraZeneca AB
    Inventors: Alistair John Boyd, Alexander Telford